Single-ingredient riboflavin,
does it really help with Reduction of hs-CRP in adults with elevated hs-CRP?
research showsHuman research on B2 and CRP exists, but the documented search did not identify an eligible comparison clearly verifying high-sensitivity CRP results in a population selected for elevated hs-CRP. The current judgment for this narrow question is ? with no numerical score. It means neither that B2 has no effect nor that it treats inflammatory disease.
ads claimAdvertising and mechanistic claims were not used as grade bonuses or direct clinical evidence.
Four separate assessment dimensions
| Effect direction and size | Human research on B2 and CRP exists, but the documented search did not identify an eligible comparison clearly verifying high-sensitivity CRP results in a population selected for elevated hs-CRP. The current judgment for this narrow question is ? with no numerical score. It means neither that B2 has no effect nor that it treats inflammatory disease. |
|---|---|
| Evidence certainty | ? and null are applied to the documented search under molecule, route, elevated-hs-CRP population and high-sensitivity endpoint criteria. This does not erase existing indirect CRP research. A single inaccessible source is not treated as absence; population, assay and design limitations are listed for each candidate. E0 and repeated refutation were not established, so F is not used. |
| Applicability | Adults defined by elevated hs-CRP; results from different underlying diseases are not pooled |
| Safety | Safety for the eligible population, product and duration is unconfirmed. Tolerability in short studies of other populations is not generalized to long-term safety, and hs-CRP change is distinguished from clinical anti-inflammatory benefit. |
Not official GRADE or treatment-success probability; ? has no score.
Useful facts when choosing a product
- Ordinary single-ingredient oral B2 is the fixed question. Dose, release profile, baseline B2 status and total dietary intake in an eligible study remain unconfirmed. A CRP figure unit is not converted into an hs-CRP unit without verification.
Chamgap Semantic Classification Code
Permanent code issued
S.riboflavin.oral.elevated-hscrp.reduce.placebo-or-no-additionSupplements > Single-ingredient riboflavin > Oral > Elevated hs-CRP > Reduction claim > Placebo or no addition
Technically bound to the current-value claim boundary fixed by ChatGPT. Unconfirmed dose, duration, study details, and evidence grade remain in verdict fields and revision history rather than the permanent semantic code. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Single-ingredient riboflavin (vitamin B2) |
| Source or part used | Synthetic/fermentation/other production origin unconfirmed; plant-part classification not applicable |
| Formulation or processing | Question: ordinary oral B2 alone; not automatically combined with colon-targeted formulations |
| Route | Oral (page question; see observed_evidence for study-route verification) |
| Dose | Dose in an eligible elevated-hs-CRP study unconfirmed |
| Duration | Duration in an eligible elevated-hs-CRP study unconfirmed |
| Population | Adults defined by elevated hs-CRP; results from different underlying diseases are not pooled |
| Effect or condition | Reduction of hs-CRP in adults with elevated hs-CRP |
| Primary endpoint | Change in high-sensitivity CRP; distinct from ordinary CRP, other inflammatory markers and clinical anti-inflammatory benefit |
| Comparator | Question: placebo/no addition on matched usual care; comparative results for the specified population and assay unconfirmed |
| Duplicate-detection key | riboflavin-single|oral|dose-unconfirmed|duration-unconfirmed|elevated-hscrp-adults|hscrp-change|placebo-or-no-addition-question |
What the research actually shows
An older-adult placebo trial with a nonsignificant CRP result, a Crohn-disease before/after CRP study and a healthy-volunteer redox analysis have different designs and populations. Assay sensitivity, an elevated-hs-CRP entry criterion and contemporaneous comparison must match the same question. The result body of a registry candidate found in the search was not obtained.
Why this is classified as ?
? and null are applied to the documented search under molecule, route, elevated-hs-CRP population and high-sensitivity endpoint criteria. This does not erase existing indirect CRP research. A single inaccessible source is not treated as absence; population, assay and design limitations are listed for each candidate. E0 and repeated refutation were not established, so F is not used.
Counterpoint. The nonsignificant ordinary-CRP result is retained, but it is not transferred into a precise null result for this hs-CRP question. An uncontrolled before/after decrease or correlation with another marker is likewise not recast as a confirmed B2 treatment effect.
Rejudgment record. Human research on B2 and CRP exists, but the documented search did not identify an eligible comparison clearly verifying high-sensitivity CRP results in a population selected for elevated hs-CRP. The current judgment for this narrow question is ? with no numerical score. It means neither that B2 has no effect nor that it treats inflammatory disease. — ? and null are applied to the documented search under molecule, route, elevated-hs-CRP population and high-sensitivity endpoint criteria. This does not erase existing indirect CRP research. A single inaccessible source is not treated as absence; population, assay and design limitations are listed for each candidate. E0 and repeated refutation were not established, so F is not used.
| Endpoint | S | Surrogate marker - laboratory or imaging measures Case application: Defines the question, not an observed eligible trial; unused scoring axes remain null |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
Results jointly confirming a high-sensitivity assay and selection for elevated hs-CRP unconfirmed Registry result body inaccessible A B6–B2 metabolic-interaction paper surfaced in discovery, but its full content was not verified and no B2 treatment effect was adopted Native databases worldwide were not exhaustively searched; the current judgment is published with that limitation.
Search scope and limitations. tasks/R01-007/search_log.json
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Tavares et al. — riboflavin, homocysteine and C-reactive protein in older adults (2009) | Excluded: population/assay eligibility not established | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | CRP and homocysteine in older adults; qualifying high-sensitivity assay unverified | The placebo-controlled older-adult study included 42 participants, B2 10 mg/day and 28 days; it reported no significant CRP effect. Selection for elevated hs-CRP and a high-sensitivity assay were not verified. | Excluded: population/assay eligibility not established |
| von Martels et al. — RISE-UP riboflavin study in Crohn disease (2020) | Excluded: population/assay/design do not establish eligibility | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Before/after CRP and disease-related measures in Crohn disease, not a randomized concurrent comparison | RISE-UP was a before/after study in 70 people with Crohn disease using B2 100 mg/day for 3 weeks. It lacked a contemporaneous randomized control; some findings concerned fecal-calprotectin strata. | Excluded: population/assay/design do not establish eligibility |
| Bourgonje et al. — riboflavin and systemic redox status (2022) | Excluded: different population or endpoint | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Systemic redox status and CRP association analyses in healthy volunteers | The healthy-volunteer RIBOGUT redox analysis and correlations with CRP are not a randomized B2 effect in a population selected for elevated hs-CRP. | Excluded: different population or endpoint |
| Clinical trial record NCT05803811 | Registry candidate; result body not verified | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Official registry results and endpoint details unverified | Registry results and detailed release formulation were not directly verified. Numbers in discovery summaries were not adopted. | Registry candidate; result body not verified |
Receipt — 4 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-15 · current_value_initial_publication — CRP was not automatically substituted for hs-CRP; unverified sponsor-summary numbers and unit conversions were not adopted.
Cite this verdict
[Chamgap] Single-ingredient riboflavin (vitamin B2) × Reduction of hs-CRP in adults with elevated hs-CRP — Evidence Grade ?. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/oral-riboflavin-elevated-hscrp/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.